EU Q3 Results Round-Up: Karo Pharma, Probi, Ipsen
Executive Summary
Round-up of Q3 sales and earnings results for European health and wellness players, featuring Karo Pharma, Probi and Ipsen.
You may also be interested in...
Probi Grows China Reach With Sinopharm deal
Sinopharm – one of China’s largest pharmaceutical and healthcare companies – will launch in its local market three premium probiotic supplements based upon Probi’s patented strains.
Ipsen Weighing Consumer Business Sale After Challenging 2020
Ipsen CEO David Loew has kicked off a strategic review of the company's "non core" Consumer Healthcare business, which has endured a particularly tough year thanks to the COVID-19 pandemic.
Marinomed Takes Virus-Blocking Device Into Allergy And Dry Eye Categories
Virus-blocking compound Carragelose, out-licensed to major consumer health players such as Perrigo and Reckitt for use in OTC respiratory nasal sprays, is being adapted for use in the dry eye and allergy categories.